Anagenic replied on availability of gt20029 3/10/2023
The conversation is about the availability of gt20029 for hair loss treatment, indicating that it will not be available for purchase soon. No specific treatments were discussed.
View this post in the Community →
Similar Community Posts Join
6 / 6 resultscommunity Been off Tressless for a few years - what’s the latest on GT20029?
GT20029 is an experimental topical treatment for male-pattern hair loss, showing promising results in Phase 2 trials and moving towards Phase 3. It aims to degrade androgen receptors in hair follicles, differing from treatments like finasteride and minoxidil.
community GT20029 Will Replace Finasteride For Hair Loss
GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.
community GT20029: How It Works for Hair Loss - Hair Loss “Cure”
GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.
community GT20029 Big Phase 2 Update Results!
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
community GT20029 Phase 2 results are out
GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.
community Where are we with GT20029 ? Realistic Timeline ?
GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.
Related Research
6 / 6 resultsresearch Methodologic considerations in evaluating early clinical outcomes of GT20029 for androgenetic alopecia
This source discusses a Phase 2 trial by Hu et al. that evaluated the efficacy of topical GT20029 compared to a placebo, though the abstract does not provide specific results.
research Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
This randomized trial found that topical GT20029 significantly increased hair counts and width in Chinese men with androgenetic alopecia over 12 weeks, showing better results than placebo, with the 0.5% once daily and 1.0% twice weekly doses particularly effective.
research Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
In this multicenter Phase II trial, researchers found that topical GT20029 significantly increased hair regrowth in Chinese adult males with androgenetic alopecia compared to placebo, demonstrating good tolerability and suggesting the need for further studies to confirm its therapeutic potential.
research Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
This Phase II trial found that topical GT20029 significantly increased hair count and width at 12 weeks in Chinese men with androgenetic alopecia compared to placebo, with good tolerability and similar adverse event incidence across groups.
research Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.
research Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment
This review highlights the potential of PROTACs to transform cancer treatment by selectively degrading oncogenic proteins, overcoming drug resistance, and reducing toxicity; it also discusses challenges in optimizing these therapies for personalized applications.